変異性AR-LBDにおけるリガンド誘発型変化の暴露:アンドロゲン受容体-共活性化メカニズムに関する分子動態の洞察
Madiha Sardar1, Nadeem Ahmad1, Mamona Mushtaq2
1H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.
Journal of chemical information and modeling
|August 22, 2025
まとめ
アンドロゲン受容体 (AR) 変異は,ARを対抗状態から対抗状態に変化させ,前立腺がん治療の有効性を低下させることがあります. この研究は,AR-LBD変異がコアクティベーターの相互作用をどのように変化させ,このシフトを促し,新しい治療標的を提供することを明らかにしています.
科学分野:
- 分子生物学と構造生物学
- 計算式生体物理学
- 癌の研究
背景:
- アンドロゲン受容体 (AR) は遺伝子発現,性現象型,前立腺がん (PCa) の発現に不可欠である.
- DHTのようなアゴニストによるAR活性化には,形状の変化とコアクティベーターの相互作用が含まれます.
- ARアンタゴニスト (例えば,アパルウタミド) はPCaを治療しますが,AR- LBD変異のために有効性を失います.
研究 の 目的:
- 変異したAR-LBDにおけるリガンド誘発の形状の変化を調査する.
- これらの変化がAR同活性化剤の相互作用に与える影響を明らかにする.
- 抗体から抗体への状態変換の背後にあるメカニズムを理解する.
主な方法:
- 多重複製 (10.5μs合計) の分子動力学シミュレーション
- 形状の変化とAR-共活性剤の相互作用の分析
- 自由エネルギー分解計算,ダイナミック・クロス・コレレーション・マトリックス,主成分分析,自由エネルギー風景計算.
主要な成果:
- DHTはAR活性化機能-2 (AF-2) 領域を安定させ,共活性化剤の相互作用を促進する.
- アンタゴニストはヘリックス12の変化を誘導し,コアクティベーターの相互作用を乱します.
- F876LおよびT877A変異はアロステル経路を変化させ,AR- アパルタミド複合体をアゴニスティック状態に変換する可能性があります.
- AR変異系は,電静相互作用とコンフォーマーションエントロピーの影響を受け,対抗性ARよりも高い結合親和性を示します.
結論:
- AR-LBDの点変異は,ARとAF-2の構造を変えることで,ARを対抗状態から対抗状態に変化させます.
- このシフトはコアクティベーターの継続的な募集と持続的なAR活動につながり,治療の有効性を低下させます.
- 発見はAR-コアクティベーターの相互作用に関する洞察を提供し,カストレーション抵抗性前立腺がんの治療法の開発を助けます.
関連する概念動画
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Cooperative Allosteric Transitions
8.0K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.0K
Ligand Binding Sites
13.2K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.2K
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
GPCR Desensitization
6.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.5K
Assembly of Signaling Complexes
5.9K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.9K


